Viridian Shares New 52-Week Phase III Trial Data for Active TED
New THRIVE trial data highlight long-term proptosis response with veligrotug in thyroid eye disease patients. Fresh long-term data is showing…
FDA Grants RMAT Designation to Atsena Therapeutics’ Gene Therapy for X-linked Retinoschisis
The designation aims to expedite development of ATSN-201 for X-linked retinoschisis, a rare inherited retinal disease with no approved treatment.The…
latest posts